10/19/2005 5:13:14 PM
Tokyo (JCNN) - Takeda Pharmaceutical (TSE: 4502) and Toray Industries (TSE: 3402) announced today that the companies have concluded a joint development and marketing agreement on an investigational compound for frequent urination/urinary incontinence.
Under the terms of the agreement, Takeda and Toray will jointly develop the compound, while Toray will market in Japan and Takeda will market overseas. The partners hope this collaboration will enable the efficient development processes and the earliest possible commercialization of this compound.
The compound is now in the preparation stage for Phase I studies in the U.S.
comments powered by